Pharmacovigilance
Pharmacovigilance, the science and activities relating to detecting, assessing, understanding and preventing adverse effects, is critically important in paediatric drug development because children may be more susceptible than adults to certain adverse effects and because the long-term developmental consequences of early drug exposure may not become apparent for years or decades.
Paediatric pharmacovigilance spans both the pre-approval and post-approval phases of a medicine’s life cycle, each addressing a different part of the safety evidence gap. In the pre-approval phase, paediatric clinical trials are typically underpowered to detect rare or delayed adverse events, given smaller patient sample sizes, shorter follow-up periods and the ethical and practical constraints of paediatric research. Safety monitoring in early phases at this stage therefore focuses on identifying signals related to growth, neurodevelopment and organ maturation, often through age-stratified safety endpoints and extended observation periods built into trial design. See Module 2 for more about detecting and reporting adverse events in the pre-approval trial phases.
In the post-approval phase, pharmacovigilance systems shift toward real-world signal detection and long-term surveillance, using tools such as spontaneous adverse event reporting, paediatric-specific registries, sentinel surveillance networks and electronic health record–based pharmacoepidemiology studies to capture rare events, off-label use patterns and delayed effects across the full growth trajectory into adolescence and adulthood. Because children are also frequently exposed to medicines off-label or in formulations not specifically evaluated for paediatric use, post-approval pharmacovigilance plays a role in generating the safety evidence that pre-approval trials cannot feasibly provide, making the two phases complementary and equally essential components of ensuring that medicines are safe for children across the full span of development.
Post-authorization safety studies
Post-authorization safety studies are conducted to obtain further information on the safety of a paediatric medicine after authorization, particularly where important safety questions remain following pre-authorization clinical development. Post-authorization safety studies may be used to characterize known or potential risks, identify rare or unexpected adverse events and assess long-term safety and developmental outcomes for children, including outcomes that may not be observable within the duration or size of pre-authorization trials. Post-authorization safety studies can also address specific safety concerns identified by regulatory authorities and support regulatory commitments and post-marketing requirements, contributing to ongoing assessment and management of the medicine’s benefit–risk profile. Post-authorization safety studies can be imposed, required by regulatory authorities of post-marketing authorization holders, or voluntary, sponsored or conducted by post-marketing authorization holders on their own initiative.
Real-world data and evidence for post-approval surveillance
Beyond formal post-authorization safety studies, real-world data and real-world evidence can support continuous monitoring of paediatric medicines once they are in routine use. These approaches can provide evidence on product performance and effectiveness in broader and more diverse populations, including children and age groups underrepresented in clinical trials; monitor patterns of product utilization, dosing, adherence, off-label use and switching; and identify emerging safety or effectiveness signals. Real-world data and evidence can therefore complement spontaneous safety reporting and clinical studies, inform updates to product information and clinical guidance and help to identify evidence gaps requiring further investigation.